CN1155403C - 杀细菌／通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用 - Google Patents

杀细菌／通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用 Download PDF

Info

Publication number
CN1155403C
CN1155403C CNB971957282A CN97195728A CN1155403C CN 1155403 C CN1155403 C CN 1155403C CN B971957282 A CNB971957282 A CN B971957282A CN 97195728 A CN97195728 A CN 97195728A CN 1155403 C CN1155403 C CN 1155403C
Authority
CN
China
Prior art keywords
application
leu
ser
bpi
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB971957282A
Other languages
English (en)
Chinese (zh)
Other versions
CN1222859A (zh
Inventor
P��J��ŵ��
P·J·斯卡诺恩
N·维德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Xoma Royalty Corp
Original Assignee
Xoma Corp
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp, Xoma Technology Ltd USA filed Critical Xoma Corp
Publication of CN1222859A publication Critical patent/CN1222859A/zh
Application granted granted Critical
Publication of CN1155403C publication Critical patent/CN1155403C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB971957282A 1996-05-23 1997-05-23 杀细菌／通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用 Expired - Fee Related CN1155403C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65229296A 1996-05-23 1996-05-23
US08/652,292 1996-05-23

Publications (2)

Publication Number Publication Date
CN1222859A CN1222859A (zh) 1999-07-14
CN1155403C true CN1155403C (zh) 2004-06-30

Family

ID=24616300

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971957282A Expired - Fee Related CN1155403C (zh) 1996-05-23 1997-05-23 杀细菌／通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用

Country Status (10)

Country Link
US (2) US5945399A (de)
EP (1) EP0907372B1 (de)
JP (1) JP2000511190A (de)
CN (1) CN1155403C (de)
AT (1) ATE234111T1 (de)
AU (1) AU736096B2 (de)
CA (1) CA2255539C (de)
DE (1) DE69719754D1 (de)
NZ (1) NZ332954A (de)
WO (1) WO1997044056A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US6214789B1 (en) * 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6528255B1 (en) * 1997-12-30 2003-03-04 Genencor International, Inc. Proteases from gram positive organisms
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
CA2350628A1 (en) * 1998-11-12 2000-05-18 Polymer Biosciences, Inc. Hemostatic polymer useful for rapid blood coagulation and hemostasis
US6162237A (en) * 1999-04-19 2000-12-19 Chan; Winston Kam Yew Temporary intravascular stent for use in retrohepatic IVC or hepatic vein injury
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
AU2002361902A1 (en) * 2001-12-31 2003-07-24 Ares Medical, Inc. Hemostatic compositions and methods for controlling bleeding
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
WO2007042169A2 (en) * 2005-10-07 2007-04-19 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Matrix metalloproteinase 11 vaccine
CN2887006Y (zh) * 2005-11-30 2007-04-04 富士康(昆山)电脑接插件有限公司 电子装置的屏蔽构造
US20070248653A1 (en) * 2006-04-20 2007-10-25 Cochrum Kent C Hemostatic compositions and methods for controlling bleeding
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
CN106020478B (zh) * 2016-05-20 2019-09-13 青岛海信电器股份有限公司 一种智能终端操控方法、装置和智能终端

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5245013A (en) * 1985-04-30 1993-09-14 Richard Ulevitch Acute phase protein modulating endotoxic activity of lipopolysaccharides, assay methods and polypeptides
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
EP0652230B1 (de) * 1987-08-11 2005-12-14 New York University Biologisch-aktive Bakterizide/permeabilitätserhöhende Proteinbruchstücke
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
FI920450A7 (fi) * 1989-08-01 1992-01-31 Scripps Clinic And Res Foundation Menetelmiä ja koostumuksia verenmyrkytyksen oireiden estämiseksi
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
EP0605653A4 (de) * 1991-09-26 1995-03-15 Incyte Pharma Inc Neue art eines liposaccharid bindendes protein (lbp).
US5643570A (en) * 1992-05-19 1997-07-01 Xoma Corporation BPI-immunoglobulin fusion proteins
ES2132239T3 (es) * 1992-05-19 1999-08-16 Xoma Corp Metodos mejorados para la preparacion de proteinas de union a endotoxinas.
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
PT682524E (pt) * 1993-02-02 2002-03-28 Xoma Technology Ltd Composicoes farmaceuticas que contem a proteina bactericida indutora da permeabilidade e um agente tensioactivo
EP0690720B1 (de) * 1993-03-12 2001-06-27 XOMA Technology Ltd. Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
DE69412243T2 (de) * 1993-03-12 1999-03-25 Xoma Corp., Berkeley, Calif. Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
DE69410254T2 (de) * 1993-03-12 1998-12-17 Xoma Corp., Berkeley, Calif. Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
AU6522794A (en) * 1993-03-22 1994-10-11 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
JPH08511682A (ja) * 1993-04-30 1996-12-10 インサイト ファーマシューティカルズ，インク． 組み換えｂｐｉ蛋白およびｌｂｐ蛋白、それをコードする核酸分子、その生産方法並びにそれらの使用
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
EP0726944B1 (de) * 1993-07-02 2002-12-18 Incyte Pharmaceuticals, Inc. Glycosilierte und nichtglycolisierte bakterizide/die permeabilität erhoehende proteine und methoden zu ihrer herstellung
AU7330994A (en) * 1993-07-14 1995-02-13 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
CN1133634A (zh) * 1993-09-22 1996-10-16 爱克斯欧玛公司 定量体液中的bpi的方法
JPH09502987A (ja) * 1993-09-22 1997-03-25 ゾーマ コーポレイション 殺菌性／浸透性が向上した（ｂｐｉ）タンパク質生成物および抗生物質の投与によるグラム陰性細菌感染の治療方法
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
DE69433848T2 (de) * 1993-10-05 2005-05-25 Xoma Technology Ltd., Berkeley Bpi-protein-produkte für definierte funktionen des reticuloendothelialen systems
DE69526216T2 (de) * 1994-01-14 2002-11-14 Xoma Technology Ltd., Berkeley Antifungaleverfahren und mitteln
EP0754050B1 (de) * 1994-01-14 2002-06-26 XOMA Technology Ltd. Anti gram positive bakterielle verfahren und mittel
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
AU709738B2 (en) * 1994-09-15 1999-09-02 Xoma Corporation Anti-fungal peptides
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries

Also Published As

Publication number Publication date
EP0907372A1 (de) 1999-04-14
CN1222859A (zh) 1999-07-14
WO1997044056A1 (en) 1997-11-27
DE69719754D1 (de) 2003-04-17
US5756464A (en) 1998-05-26
JP2000511190A (ja) 2000-08-29
NZ332954A (en) 2000-07-28
AU736096B2 (en) 2001-07-26
EP0907372B1 (de) 2003-03-12
AU3369397A (en) 1997-12-09
CA2255539C (en) 2005-09-27
ATE234111T1 (de) 2003-03-15
US5945399A (en) 1999-08-31
CA2255539A1 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
CN1155403C (zh) 杀细菌／通透性增加蛋白在制备用于治疗创伤出血病人的药物中的应用
CN1105574C (zh) 杀菌/增强通透性蛋白质产物的治疗用途
AU735058B2 (en) Therapeutic uses of BPI protein products for human meningococcemia
US7696158B2 (en) Use of IL-22 for the treatment of conditions of metabolic disorders
CN1112933C (zh) 抗真菌的方法和物质
CN1157290A (zh) 重组肥胖(ob)蛋白
CN1145033A (zh) Bpi蛋白产物的人类治疗性应用
JPH11508895A (ja) 糖尿病を処置する方法
CN1604787A (zh) 通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病
CN1273598C (zh) 杀菌/透性增加蛋白缺失类似物
CN1816345A (zh) 伴有组织破坏的疾病的预防剂和/或治疗剂
CN1323216A (zh) 重组人类子宫珠蛋白在炎症类和纤维变性类疾病治疗中的应用
CN120173090B (zh) 猫血清白蛋白突变体、及其cho细胞表达方法和应用
US7074399B2 (en) Treatment of inflammation with p20
MXPA98009760A (en) Therapeutic uses of bpi protein products in human beings with bleeding due to tra
Scannon Therapeutic uses of BPI protein products for human meningococcemia
AU2007202500A1 (en) Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
WO1997005897A1 (en) Remedy for coxsackie virus b infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: American California

Applicant after: Xoma Technology Ltd.

Address before: Bermuda Hamilton

Applicant before: Eyck Soma Ltd

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: AIKESONME CO., LTD. TO: XOMA TECHNOLOGY LTD.

C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee